Market Overview

PolyMedix to Review Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic

PolyMedix (OTC: PYMX) has scheduled a conference call and webcast for Wednesday, December 7 at 9:00 AM Eastern Time. At that time, management will review the results of the interim analysis from the ongoing Phase 2 clinical study with PMX-30063, defensin-mimetic antibiotic in treating patients with Staph Acute Bacterial Skin and Skin Structure Infections. This is the first clinical study ever conducted in patients with Staph infections with this new class of antibiotic – a defensin-mimetic.

Posted-In: News FDA

 

Related Articles (PYMX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters